Mini review: genome and transcriptome editing using CRISPR-cas systems for haematological malignancy gene therapy.

Transgenic Research
Esther K ElliottLyn R Griffiths

Abstract

The recent introduction of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated protein (Cas) systems, offer an array of genome and transcriptome editing tools for clinical repair strategies. These include Cas9, Cas12a, dCas9 and more recently Cas13 effectors. RNA targeting CRISPR-Cas13 complexes show unique characteristics with the capability to engineer transcriptomes and modify gene expression, providing a potential clinical cancer therapy tool across various tissue types. Cas13 effectors such as RNA base editing for A to I replacement allows for precise transcript modification. Further applications of Cas13a highlights its capability of producing rapid diagnostic results in a mobile platform. This review will focus on the adaptions of existing CRISPR-Cas systems, along with new Cas effectors for transcriptome or RNA modifications used in disease modelling and gene therapy for haematological malignancy. We also address the current diagnostic and therapeutic potential of CRISPR-Cas systems for personalised haematological malignancy.

References

Feb 7, 2001·Genes & Development·S M ElbashirT Tuschl
Nov 17, 2007·Cell Death and Differentiation·Andrew Z Fire
Nov 9, 2011·Annual Review of Genetics·Devaki BhayaRodolphe Barrangou
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Sep 6, 2012·Proceedings of the National Academy of Sciences of the United States of America·Giedrius GasiunasVirginijus Siksnys
Jan 5, 2013·Science·Le CongFeng Zhang
Oct 8, 2013·Trends in Microbiology·Giedrius Gasiunas, Virginijus Siksnys
Oct 26, 2013·Nature Protocols·F Ann RanFeng Zhang
Mar 22, 2014·Human Molecular Genetics·Feng ZhangXiong Guo
Oct 3, 2014·Nature·Mitchell R O'ConnellJennifer A Doudna
Nov 29, 2014·Science·Jennifer A Doudna, Emmanuelle Charpentier
Apr 17, 2015·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·David A NellesGene W Yeo
Oct 17, 2015·Molecular Cell·Yan ZhangErik J Sontheimer
Nov 5, 2015·The FEBS Journal·Rongxue PengJinming Li
Dec 25, 2015·Genome Biology·Jennifer A Doudna, Charles A Gersbach
Mar 22, 2016·Cell·David A NellesGene W Yeo
Apr 8, 2016·Blood·Donald B KohnAndrew M Scharenberg
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Jul 14, 2016·The Journal of Allergy and Clinical Immunology·Chantal Lagresle-PeyrouIsabelle Andre-Schmutz
Aug 26, 2016·Nucleic Acids Research·Maria Fernanda Montiel-GonzálezJoshua J C Rosenthal
Nov 7, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jiangtao RenYangbing Zhao
May 6, 2017·Molecular Cell·Alexandra East-SeletskyJennifer A Doudna
Jun 29, 2017·Genome Medicine·James C KaczmarekDaniel G Anderson
Oct 5, 2017·Nature·Omar O AbudayyehFeng Zhang
Oct 27, 2017·Science·David B T CoxFeng Zhang
Oct 31, 2017·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Wei Leong Chew
Mar 20, 2018·Cell·Silvana KonermannPatrick D Hsu
Mar 21, 2018·Frontiers in Immunology·Gabrielle BradshawLyn R Griffiths
Apr 19, 2018·Blood·Laura Pasqualucci, Riccardo Dalla-Favera
Apr 25, 2018·Current Research in Translational Medicine·Xiaojun Liu, Yangbing Zhao
Apr 28, 2018·Science·Cameron MyhrvoldPardis C Sabeti
Jun 13, 2018·The Biochemical Journal·Ayman EidMagdy M Mahfouz
Jul 5, 2018·Journal of Medical Genetics·An-Liang XiaXiao-Jie Lu
Sep 10, 2018·Molecular Therapy. Nucleic Acids·Carsten T CharlesworthMatthew H Porteus
Jan 18, 2019·Molecular Therapy. Nucleic Acids·Colette MosesPilar Blancafort
Jan 30, 2019·Nature Medicine·Carsten T CharlesworthMatthew H Porteus
Mar 30, 2019·Haematologica·Elisa González-RomeroAlejandra Sanjuan-Pla
May 30, 2019·Frontiers in Pediatrics·Sarah E HenricksonJennifer R Heimall
Jun 20, 2019·Methods : a Companion to Methods in Enzymology·William C SkarnesJustin A McDonough
Oct 22, 2019·Nature·Andrew V AnzaloneDavid R Liu
Feb 8, 2020·Science·Edward A StadtmauerCarl H June

Related Concepts

Gene Expression
Gene Therapy
Genes
Genome
RNA
Immune Effector Cell
Hematologic Neoplasms
Cancer Treatment
Array
Clinical Treatment

Related Feeds

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.